Immunocore Holdings plc (IMCR)
Immunocore Holdings Plc operates as a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease. Its lead product KIMMTRAK is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma, in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others. The company was founded on January 7, 2021 and is headquartered in Abingdon, the United Kingdom.
Address
90 PARK DRIVE
OXFORDSHIRE, X0 OX14 4RY
Founded
2021
Number of Employees
497
Website
http://www.immunocore.com
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)